Search results
Results from the WOW.Com Content Network
A blood test including platelets and a clotting screen should be performed prior to administration of anticoagulant regimens in pregnancy. [ 13 ] Subcutaneous tinzaparin may be given at doses of 175 units of antifactor Xa activity per kg, [ 13 ] based on prepregnancy or booking weight at approximately 16 weeks, and not the current weight. [ 13 ]
Proton-pump inhibitors have largely superseded the H 2-receptor antagonists, a group of medications with similar effects but a different mode of action, and heavy use of antacids. [3] A potassium-competitive acid blocker (PCAB) revaprazan was marketed in Korea as an alternative to a PPI.
Use in pregnancy and breastfeeding is of unclear safety. [5] It works by blocking H + /K +-ATPase in the parietal cells of the stomach. [3] Dexlansoprazole was approved for medical use in the United States in 2009. [3] In Canada in 2016, it was the most expensive Proton-pump inhibitor (PPI) available. [4]
A derivative of timoprazole, omeprazole, was discovered in 1979, and was the first of a new class of drug that control acid secretion in the stomach, a proton pump inhibitor (PPI). [ 11 ] [ 12 ] Addition of 5-methoxy-substitution to the benzimidazole moiety of omeprazole was also made and gave the compound much more stability at neutral pH. [ 6 ]
Lansoprazole is used for treatment of: [3] Ulcers of the stomach and duodenum, and NSAID-induced ulcers; Helicobacter pylori infection, alongside antibiotics (adjunctive treatment), treatment to kill H. pylori causing ulcers or other problems involves using two other drugs besides lansoprazole known as "triple therapy", and involves taking twice daily for 10 or 14 days lansoprazole ...
Ball-and-stick model of cimetidine, the prototypical H 2 receptor antagonist. H 2 antagonists, sometimes referred to as H2RAs [1] and also called H 2 blockers, are a class of medications that block the action of histamine at the histamine H 2 receptors of the parietal cells in the stomach. This decreases the production of stomach acid.
Sucralfate may be considered to have the advantage over H2-blockers and PPIs in this regard because sucralfate does not change the pH of gastric fluid. A majority of meta-analyses found that sucralfate therapy decreased the incidence of ventilator-associated pneumonia compared to H2-antagonists. [10]
The CYP2C19 enzyme metabolizes proton pump inhibitors (PPI) as well as clopidogrel. Various reports have stated that there is a negative clopidogrel-omeprazole drug interaction. Some studies have found that clopidogrel activity on platelets was hampered significantly by patients receiving treatment with omeprazole, a proton pump inhibitor (PPI).